CS Paper Radar

STRIDE: Spatial-Temporal Representation for Interval-conditioned Disease Evolution in Longitudinal Glioblastoma MRI

Wenhao Guo, Changchang Yin, Pierre Giglio, Weidan Cao, Ping Zhang, Golrokh Mirzaei

eess.IV cs.AIcs.CV ·submitted 2026-10-02 02:31 UTC · v1

Abstract

Glioblastoma (GBM), an aggressive primary brain tumor, is routinely monitored with longitudinal MRI after treatment. Distinguishing stable disease (SD), pseudoprogression (PsP), and true progression (TP) remains challenging because these states can show overlapping MRI appearances despite different temporal trajectories. Existing longitudinal methods still face challenges in modeling scan-specific spatial variability, variable follow-up intervals, and complementary information from the observed follow-up state and its longitudinal change. We propose STRIDE, a framework for spatial-temporal representation of interval-conditioned disease evolution that takes paired post-treatment MRI scans and their inter-scan interval as input and predicts SD, PsP, or TP. The lesion-prior-guided spatial representation combines SoftGate and an Adaptive-window Hierarchical Transformer (AWHT) to emphasize lesion-related regions while preserving surrounding context. The time-conditioned latent transition uses pair-level context and the actual inter-scan interval to estimate interval-dependent representation changes between visits. The observed--transition fusion integrates the transition-estimated follow-up representation with the directly observed follow-up representation to jointly characterize the follow-up state and its longitudinal change. BraTS2024 is used to develop and evaluate the lesion-prior generator, while longitudinal pretraining on LUMIERE supports transfer before downstream adaptation to Burdenko. On the Burdenko three-class task, STRIDE achieves a macro ROC--AUC of 0.816 and a macro F1-score of 0.796. These results support its potential for more reliable longitudinal post-treatment GBM state assessment.

Comment
37 pages, 11 figures

Closest papers

Nearest neighbours by meaning across the whole index.

How Good are Foundation Models in Longitudinal MRI Disease Progression Reasoning?

cs.CV ·2026-08-13 ·Wafa Al Ghallabi, Ritesh Thawkar, Sara Ghaboura, Omkar Thawakar, Numan Saeed +4 more
top venuebenchmarkcode/data similarity 0.71
Abstract · Accepted at MICCAI 2026 (Early Accept). 11 pages, 3 figures, 2 tables

Magnetic Resonance Imaging (MRI) interpretation is fundamental to clinical decision-making, requiring radiologists to integrate multi-view anatomical planes across sequential timepoints while precisely localizing interval changes. However, existing vision-language benchmarks remain confined to single-timepoint, single-view interpretation, failing to capture the temporal-spatial reasoning essential to radiologic practice. We introduce the Time-Aware Multi-View MRI Benchmark, an evaluation framework unifying multi-view anatomical input, temporal reasoning across longitudinal scans, and structured localization guidance. The benchmark comprises 3,920 expert-verified question-answer pairs derived from 890 patients across over 3,200 longitudinal MRI timepoints, drawn from seven clinical cohorts covering glioblastoma, neurodegeneration, vestibular schwannoma, and brain metastases, in open-ended, multiple-choice, and binary formats, requiring models to identify anatomical regions of maximal change, characterize progression across sequences and views, and provide structured guidance specifying boundaries, imaging features, and confounders. Experiments across 16 vision-language models reveal moderate temporal alignment but systematic failure on change direction recognition and volumetric quantification, while multi-view inputs improve spatial localization yet degrade temporal reasoning in compact architectures. Our benchmark provides a systematic framework for evaluating progression tracking, interval change localization, and temporal ordering, which are essential for clinical deployment. Code, evaluation splits, and the dataset are available at: https://github.com/wafaAlghallabi/Time-Aware-MRI.

0.56

Observation-Anchored Selective Assimilation for Longitudinal Tumor-State Proxy Forecasting in Post-Treatment Glioma

cs.LG cs.AI ·2026-09-11 ·Yeonjae Jung, Minwoo Shin
code/data similarity 0.70
Abstract

Post-treatment MRI in patients with glioma provides serial observations for updating patient-specific tumor-state proxy estimates, but variable appearances and trajectories complicate forecasting. We formulate forecasting as an observation-aware digital-twin update in which an intermediate observation anchors the patient-specific state. Among 203 patients and 594 follow-up time points, a predefined no-new-treatment criterion retained 120 of 236 candidate triplets, split into 81/24/15 training/validation/test triplets at the patient level. Each time point was represented by a continuous voxel-wise tumor-state proxy map in [0,1] derived from MRI lesion labels. A SegMamba-based single-step forecaster predicted update proposals from multimodal source-state tensors. Observation-Anchored Selective Assimilation (OASA) retained the observed intermediate proxy as the state anchor and selectively applied updates through a validation-selected tiered case-level rule and voxel-wise soft gate. We compared initial-scan forecasting, rollout without assimilation, latest-observation persistence, direct prediction, OASA, OASA + calibration, and morphological dilation. Checkpoints, OASA rules, and calibration thresholds were selected using validation data only. Across three seeds on 15 held-out test triplets, OASA maintained Dice at $τ$ = 0.2 comparable to persistence (0.6071 $\pm$ 0.0025 vs. 0.6070) while yielding numerically higher Dice at $τ$ = 0.5 (0.4269 $\pm$ 0.0079 vs. 0.3981), with a small RMSE increase. Calibration increased Dice at $τ$ = 0.2 to 0.6178 $\pm$ 0.0025, increased false-positive (FP) support (11,836$\rightarrow$18,663), and reduced false-negative (FN) support (22,107$\rightarrow$17,536). This reflects near-threshold support calibration rather than improved biological predictive capability. Code is publicly available at https://github.com/jsudg436/longitudinal-proxy-forecasting.

0.29

GliomaINK: A Tumor and Anatomy Conditioned Flow Matching Framework for 3D MRI Sequence Synthesis in Glioma Patients

eess.IV cs.CVq-bio.TO ·2026-10-16 ·Moinak Bhattacharya, Annie Singh, Mohammad Chaudhry, Prateek Prasanna, Gagandeep Singh
similarity 0.65
Abstract

Background: Incomplete multiparametric MR examinations limit glioma characterization and downstream AI tools. Generative models can synthesize missing MRI sequences, but anatomical structure and clinically relevant tumor features are challenging to preserve. We propose GliomaINK, an anatomy-guided conditional flow matching framework for cross-sequence 3D brain MRI synthesis. Methods: A 3D SwinUNETR predicted the conditional velocity field while an auxiliary topology-preserving loss encouraged structural consistency. The model was trained on 1,083 patients from the BraTS-AG dataset and independently tested on an in-house clinical cohort. Downstream tasks include image quality, tumor segmentation, IDH1 mutation-status prediction, and overall survival prediction. Two radiologists independently evaluated the anatomical fidelity, pathological representation, and overall image quality of the synthesized images. Results: GliomaINK exhibited the highest PSNR across all six MRI translation directions in both evaluation cohorts. In the BraTS-AG test set, the PSNR reached $25.64\pm0.55$ dB for the T2W-to-T1C synthesis, compared with $13.78\pm0.32$ dB for Pix2Pix and $18.90\pm0.53$ dB for SPADE. For downstream tumor segmentation, the method showed strong performance across tumor subregions with Dice scores reaching $0.928\pm0.014$ for edema, and $0.885\pm0.040$ for enhancing tumor. For the IDH1 mutation-status prediction, GliomaINK achieved the highest AUROC score in four of the six sequence configurations, reaching $0.827\pm0.088$. Conclusion: Anatomy-guided conditional flow matching enables high-fidelity cross-sequence glioma MRI synthesis demonstrating potential for preservation of clinically relevant information in synthesized MRI and improving downstream tasks.

0.18

Spatially and Compositionally Controlled Multimodal Glioblastoma MRI Synthesis with Latent Diffusion

cs.CV ·2026-11-04 ·Steven Glass, Max Van Puyvelde, Marija Pizurica, Mia Meyer, Olivier Gevaert +1 more
similarity 0.64
Abstract

Glioblastoma exhibits substantial heterogeneity in tumour morphology and composition across MRI modalities, often making available clinical datasets highly unbalanced in terms of patient pathologies. We propose a two-stage latent diffusion model (LDM) framework for the generation of explicitly controllable 2D glioblastoma MRI scans. First, a segmentation LDM generates tumour maps conditioned on location, spatial extent, axial position, and subregion composition. Second, a modality-conditioned LDM with ControlNet generates T1, T1Gd, T2, and FLAIR images adhering to the requested segmentation. On a held-out test set, generated segmentations achieved a mean centroid error of 0.842 pixels and a subregion proportion error of 0.795 percentage points. ControlNet improved Fréchet inception distance (FID) across all four modalities, reducing pooled FID from 42.59 to 36.12. An expert reader study yielded mean quality ratings of 6.60 for real images, 6.83 for ControlNet-generated images, and 6.77 for fully synthetic images.

0.20

CFB-GBM v2.0: An Augmented Longitudinal Dataset for Multi-Modal Glioblastoma Segmentation, Radiomics, and RANO Progression Tracking

cs.CV ·2026-08-18 ·Alexandre G. Leclercq, Noémie N. Moreau, Hugo Audebert, Andros Nassar, Thomas Cochin +19 more
top venue similarity 0.62
Abstract · 9 pages, 2 figures,

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a median overall survival of 15 months. Longitudinal, multi-modal imaging datasets with comprehensive clinical and treatment data are essential to support the development of reproducible computational methods for treatment response prediction, disease progression modelling, and personalized medicine. We present CFB-GBM v2.0, an extension of our previously released CFB-GBM dataset comprising 264 GBM patients treated according to the standard Stupp protocol. The primary contribution of this release is the completion of Gross Tumour Volume (GTV) delineations across all available timepoints ($t_0$, $t_1$ and $t_2$), increasing the overall GTV completion rate from 35% to 97%. This was achieved using a nnU-Net model pre-trained on BraTS 2021 and fine-tuned on CFB-GBM ground-truth contours, with the generated segmentations validated by five radiation oncologists. From these longitudinal GTV annotations, volumetric RANO 2.0 response category labels were derived for all available temporality pairs ($t_0 \rightarrow t_1$, $t_0 \rightarrow t_2$ and $t_1 \rightarrow t_2$). To further ease dataset usability and reproducibility, brain masks computed with HD-BET and pre-computed radiomic features extracted with PyRadiomics are provided for each patient timepoint and MRI modality. Additionally, the WHO classification guideline (2016 vs. 2021) applicable to each patient's diagnosis is now explicitly documented. CFB-GBM v2.0 is publicly available on The Cancer Imaging Archive (TCIA) at https://www.cancerimagingarchive.net/collection/cfb-gbm .

0.67

Uncertainty-Guided Handshake: Efficient Human-in-the-Loop Refinement for Surgical-Grade Glioma Segmentation

cs.CV ·2026-10-01 ·Samuel Hart, Ahmad Yahya, Ahmed Karam Eldaly
theory similarity 0.62
Abstract · 12 pages

While state-of-the-art automated models for medical image segmentation achieve high mean performance, they frequently suffer from localized, catastrophic failures that preclude safe clinical deployment, particularly in neuro-oncology. Interactive segmentation frameworks mitigate this by incorporating human oversight, but traditionally impose prohibitive cognitive and temporal workloads by requiring clinicians to manually search for errors. In this project, we present an efficient, Hybrid Structural-Aleatoric Human-in-the-Loop framework for glioma segmentation that bridges the gap between automated baseline performance and surgical-grade precision, achieving sub-2.0 mm HD95 on curated benchmarks while providing safety-net routing for structural failures across real-world clinical data. By extracting voxel-wise Test-Time Augmentation (TTA) uncertainty and applying hierarchical topological filtering, our method proactively isolates high-risk structural anomalies. We comprehensively evaluated our approach on a challenging out-of-distribution clinical stress-test cohort (N = 362). Operating under a simulated Human Oracle, the framework improved the Whole Tumor (WT) Dice score from 0.891 to 0.914 and reduced the 95th percentile Hausdorff Distance (HD95) from 5.82 mm to 4.76 mm. Critically for surgical safety, the system rescued severe boundary failures in the Tumor Core, reducing mean HD95 from 17.96 mm to 14.83 mm (improving absolute TC Dice to 0.356). These spatial rescues were achieved while demanding a median interactive workload of just 11.3% of the target volume. Acknowledging this as a simulated upper bound lacking real-world cognitive friction, the framework nevertheless demonstrates a highly Pareto-efficient pathway for safely deploying clinical AI.

0.15

Detecting Brain Cancer Progression Through Signatures of Wearable Accelerometry Data

cs.LG ·2026-10-27 ·Rishit Das, Barbora Barancikova, Matt Williams
published similarity 0.62
Abstract · 13 pages, 7 figures, 4 tables. Accepted at NeurIPS 2026 TS-LIMITS Workshop

Glioblastoma and other high-grade gliomas (HGG) have a poor prognosis and are associated with progressive functional decline. The standard of care to assess progressive disease is contrast-enhanced MRI, which is expensive, claustrophobic, and performed only once every 2-3 months. Wearable accelerometers offer a non-invasive alternative for continuously monitoring patient function between clinic visits. However, accelerometry data streams are typically noisy and highly patient-specific, making conventional time series methods and summary statistics poorly suited to detecting clinically meaningful change. This work aims to classify stable versus progressive disease states by applying rough path signatures for feature extraction from wrist-worn accelerometer data. We convert accelerometer recordings from HGG patients enrolled in the BrainWear study into walking-path segments and use signature kernel maximum mean discrepancy (SigMMD) to quantify change in patients' walking behaviour. We overcome the challenge of inter-patient heterogeneity by adjusting for the natural variation in a patient's walking during stable tumour periods. This patient-specific normalisation substantially improves separation, yielding a candidate biomarker of tumour progression. Our results provide proof-of-concept evidence that signature-based analysis of wearable accelerometry can distinguish stable from progressive disease states, motivating larger longitudinal studies of continuous wearable monitoring as a digital biomarker in neuro-oncology.

0.35

Multimodal-Conditioned Latent Diffusion Models for Spatiotemporal Brain MRI Forecasting

cs.CV cs.AI ·2026-10-18 ·Antonio Scardace, Silvia Ingala, Sebastiano Battiato, Daniele Ravì
publishedcode/data similarity 0.62
Abstract · Accepted to WACV 2027

Spatiotemporal forecasting of 3D anatomical changes is a critical generative vision challenge for modeling Alzheimer's Disease (AD) progression. While brain MRI forecasting from single-modality data has advanced, other key complementary multimodal biomarkers remain underutilized. In this work, we propose the Multimodal-Conditioned Latent Diffusion Model (MC-LDM), a novel framework for patient-specific brain MRI synthesis. MC-LDM leverages multimodal biomarkers---MRI, tau-PET, Clinical Dementia Rating (CDR), and APOE4---during training, but relies only on baseline MRI, APOE4, and patient metadata at inference, reflecting realistic clinical availability. Our contributions are threefold: (1) a Latent Diffusion Model (LDM) fine-tuned via Low-Rank Adaptation (LoRA) for data-efficient learning; (2) a multimodal conditioning that integrates molecular and clinical signals to model heterogeneous disease trajectories; and (3) auxiliary predictors estimating unobserved multimodal biomarkers from MRI features and patient covariates to condition the diffusion model, removing the need for these assessments at inference. Trained on 1,355 visits from 852 subjects in the Alzheimer's Disease Neuroimaging Initiative (ADNI), MC-LDM reduces average regional volumetric MAE by 18% over the second-best baseline on an independent test set of 664 visits. To our knowledge, MC-LDM represents the first diffusion-based framework to leverage multimodal priors for MRI forecasting. This conceptual advancement enables patient-specific trajectory generation that captures aspects of AD heterogeneity not observable from structural anatomy alone, bridging the gap between rich multimodal supervision and the strict constraints of routine clinical deployment. Code is available at: https://github.com/antonioscardace/MC-LDM.

0.43